Published in BJU Int on January 01, 2011
The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. Urology (2014) 2.02
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol (2015) 1.90
Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol (2013) 1.57
Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer (2014) 1.23
Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Can Urol Assoc J (2013) 0.94
Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. BMC Urol (2014) 0.93
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol (2012) 0.87
The prognostic value of pretreatment of systemic inflammatory responses in patients with urothelial carcinoma undergoing radical cystectomy. Br J Cancer (2015) 0.83
Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer. Med Oncol (2014) 0.83
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol (2016) 0.81
Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer (2015) 0.80
Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy. Virchows Arch (2012) 0.78
Bladder Preservation for Muscle Invasive Bladder Cancer. Bladder Cancer (2016) 0.77
Retrograde radical cystectomy and consequent peritoneal cavity reconstruction benefits localized male bladder cancer: results from a cohort study. World J Surg Oncol (2015) 0.75
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol (2009) 6.71
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78
The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol (2006) 3.88
Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. J Urol (2008) 3.46
Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol (2009) 3.38
Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97
Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur Urol (2011) 2.87
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77
Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer (2008) 2.75
Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol (2012) 2.73
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
Academic ranking score: a publication-based reproducible metric of thought leadership in urology. Eur Urol (2011) 2.51
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results. Int J Radiat Oncol Biol Phys (2011) 2.23
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology (2011) 2.20
Consumers' perceptions about and use of the internet for personal health records and health information exchange: analysis of the 2007 Health Information National Trends Survey. J Med Internet Res (2010) 2.19
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys (2005) 2.08
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol (2013) 1.99
Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer (2011) 1.98
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons. BJU Int (2012) 1.87
Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer (2011) 1.80
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int (2011) 1.78
Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol (2012) 1.78
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology (2010) 1.77
Mechanism of recurrent/persistent ischemic/functional mitral regurgitation in the chronic phase after surgical annuloplasty: importance of augmented posterior leaflet tethering. Circulation (2006) 1.77
Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol (2012) 1.75
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol (2008) 1.73
Outcomes following partial nephrectomy by tumor size. J Urol (2008) 1.72
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol (2009) 1.70
Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol (2004) 1.66
A randomized trial to improve the quality of treatment for panic and generalized anxiety disorders in primary care. Arch Gen Psychiatry (2005) 1.65
Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer (2008) 1.64
Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol (2012) 1.64
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res (2005) 1.61
Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer (2009) 1.60
Enhancing renal masses with zero net growth during active surveillance. J Urol (2007) 1.59
Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol (2004) 1.58